The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse
- Charles L. Bowden MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Bipolar disorder is marked by frequent recurrences, a course from childhood or early adulthood until death, marked increased rates of suicide, and substantial functional morbidity. Maintenance treatment is generally recommended to reduce the ravages of the illness. This article reviews the evidence that lithium, divalproex, and carbamazepine may reduce suicidal risk. It reviews the evidence for relapse prevention for lithium, valproate, and other drugs often employed in the maintenance phase treatment of bipolar disorder. Both lithium and divalproex appear beneficial in prevention of relapse, although recent studies indicate more modest effects for lithium than did early studies from the 1970s.
- Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997, 170:205–228.
- Dilsaver SC, Chen YW, Swann AC, et al.: Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994, 151:1312–1315.
- Müller-Oerlinghausen B, Muser CB, Volk J: Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992, 25:261–269. CrossRef
- Simpson SG, Jamison KR: The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999, 60 Suppl 2:53–56.
- Ahrens B, Müller-Oerlinghausen B, Grof P: Length of lithium treatment needed to eliminate the high mortality of affective disorders. Br J Psychiatry 1993, 163 Suppl 21:27–29.
- Isometsa ET, Henriksson MM, Aro HM, Lonnqvist JK: Suicide in bipolar disorder in Finland. Am J Psychiatry 1994, 151:1020–1024.
- Tondo L, Baldessarini RJ, Hennen J, et al.: Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998, 59:405–414.
- Baldessarini RJ, Tondo L, Floris G, Rudas N: Reduced morbidity after gradually discontinuing lithium in bipolar I and II disorders: a replication study. Am J Psychiatry 1997, 154:551–553.
- Theis-Flechtner K, Müller-Oerlinghausen B, Seibert W, et al.: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996, 29:103–107.
- Greil W, Ludwig-Mayerhofer W, Erazo N, et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997, 43:151–161. CrossRef
- Prien RF, Caffey EM, Klett CJ: Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973, 28:337–341.
- Vestergaard P, Aagaard J: Five-year mortality in lithium-treated manic-depressive patients. J Affect Disord 1991, 21:33–38. CrossRef
- Bowden CL, Calabrese JR, McElroy SL, et al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000, 57:481–489. A large (n = 372) randomized study that provides the only blinded comparison of lithium with a mood stabilizer, and the only study to taper the mood stabilizer taken at the time of randomization, to reduce possibility of drug withdrawal-induced relapse. CrossRef
- Gitlin MJ, Swendsen J, Heller TL, Hammen C: Relapse and impairment in bipolar disorder. Am J Psychiatry 1995, 152:1635–1640.
- Coppen A, Noguera R, Bailey J, et al.: Prophylactic lithium in affective disorders. Lancet 1971, 2:275–279. CrossRef
- Cundall RL, Brooks PW, Murray LG: A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972, 2:308–311. CrossRef
- Baastrup PC, Poulsen JC, Schou M, et al.: Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorder. Lancet 1970, 2:326–330. CrossRef
- Melia PI: Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry 1970, 116:621–624.
- Stallone F, Shelley E, Mendlewicz J, Fieve RR: The use of lithium in affective disorders, III: a double-blind study of prophylaxis in bipolar disorder. Am J Psychiatry 1973, 130:1006–1010.
- Aagaard J, Vestergaard P: Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990, 18:259–266. CrossRef
- Tohen M, Watenaux CM, Tsuang MT: Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990, 47:1106–1111.
- Harrow M, Goldberg JF, Grossman LS, Meltzer HY: Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990, 47:665–671.
- Maj M, Pirozzi R, Magliano L, Bartoli L: Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998, 155:30–35. A systematic report of long-term outcomes with lithium treatment of bipolar disorder. It indicates good results among patients who stay with treatment for several years, but high rates of early failure, poor adherence, and dropouts.
- Schou M, Juel-Nielsen N, Stromgren E, Voldby H: The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954, 17:250–260.
- Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1963, 109:56–65.
- Goodwin FK, Murphy DL, Bunney WE Jr: Lithium carbonate treatment in depression and mania: a longitudinal doubleblind study. Arch Gen Psychiatry 1969, 21:486–496.
- Stokes PE, Shamoian CA, Stoll PM, Patton MJ: Efficacy of lithium as acute treatment of manic-depressive illness. Lancet 1971, 1:1319–1325. CrossRef
- Bowden CL, Brugger AM, Swann AC, et al.: Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994, 271:918–924. CrossRef
- Esparon J, Kolloori J, Naylor GJ, et al.: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986, 148:723–725. CrossRef
- Ahlfors UG, Baastrup PC, Dencker SJ: Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981, 64:226–237.
- Okuma T, Yamashita I, Takahashi R, et al.: Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990, 23:143–150. CrossRef
- Lambert PA, Venaud D: Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders. Nervure 1992, 5:57–65.
- Calabrese JR, Delucchi GA: Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990, 147:431–434.
- McElroy SL, Keck Jr, Pope Jr. HG: Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987, 7:16–24.
- Baldessarini RJ, Tohen M, Tondo L: Maintenance treatment in bipolar disorder [comment]. Arch Gen Psychiatry 2000, 57:490–492. A thoughtful editorial on the complexities of analysis of treatments for prophylaxis of bipolar disorder, with special attention to the difficulties of studying a sample fully representative of the spectrum of bipolar disorder. CrossRef
- The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse
Current Psychiatry Reports
Volume 2, Issue 6 , pp 490-494
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78229-3900, San Antonio, TX, USA